AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18827613 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense docetaxel and cisplatin with darbepoetin and pegfilgrastim without BNP7787 (Group A)
Number of subjects: 151
Study 18827613 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense docetaxel and cisplatin with darbepoetin and pegfilgrastim with BNP7787 (Group B)
Number of subjects: 151
Study 16408240 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliance therapy
Number of subjects: 0
Study 16408240 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airways pressure therapy (CPAP)
Number of subjects: 0
Study 14671142 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 10798794 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 12
Study 10798794 — intervention group
Group type: EXPERIMENTAL
Intervention: Loprazolam (2 mg)
Number of subjects: 12
Study 10798794 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study 9275691 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmosis chemotherapy (5-FU)
Number of subjects: 160
Study 9275691 — intervention group
Group type: COMPARATOR
Intervention: Control (radical resection alone)
Number of subjects: 160
Study 2000831 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium-enriched yeast (SeMet) 200 micrograms Se/d
Number of subjects: 33
Study 2000831 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenate 200 micrograms Se/d
Number of subjects: 33
Study 2000831 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no added selenium)
Number of subjects: 33
Study 2000831 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium-enriched yeast (SeMet)
Number of subjects: 33
Study 2000831 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenate
Number of subjects: 33
Study 6227078 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptotriad
Number of subjects: 0
Study 6227078 — intervention group
Group type: COMPARATOR
Intervention: Iodochlorhydroxyquinoline combinations, neomycin, phthalsulphathiazole, furazolidone, bismuth salicylates
Number of subjects: 0
Study 31273416 — intervention group
Group type: EXPERIMENTAL
Intervention: hTEE
Number of subjects: 550
Study 31273416 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 550
Study 28852205 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Bio-25; Supherb)
Number of subjects: 100
Study 28852205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 28852205 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 100
Study 26762482 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% rebamipide
Number of subjects: 40
Study 26762482 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment with rebamipide)
Number of subjects: 40
Study 24583430 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (5-15 mg/day of prednisolone and 6 mg/week of methotrexate)
Number of subjects: 17
Study 24583430 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids alone
Number of subjects: 17
Study 23071826 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of Korean trials in Cochrane reviews
Number of subjects: 742
Study 23071826 — intervention group
Group type: COMPARATOR
Intervention: Cochrane acupuncture reviews (existing trials)
Number of subjects: 742
Study 21059430 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin level <120 g/L
Number of subjects: 746
Study 21059430 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin level 120 to 139 g/L
Number of subjects: 746
Study 21059430 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin level 140 to 159 g/L
Number of subjects: 746
Study 21059430 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin level >160 g/L
Number of subjects: 746
Study 17331806 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-mm circular stapler
Number of subjects: 200
Study 17331806 — intervention group
Group type: COMPARATOR
Intervention: 25-mm circular stapler
Number of subjects: 200
Study 16158206 — intervention group
Group type: EXPERIMENTAL
Intervention: Crohn disease
Number of subjects: 129
Study 16158206 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcerative colitis
Number of subjects: 129
Study 12434609 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus thermodilution cardiac output (BCO)
Number of subjects: 24
Study 12434609 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous thermodilution cardiac output (CCO)
Number of subjects: 24
Study 12434609 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal echo-Doppler ultrasonography (ED-CO)
Number of subjects: 24
Study 10599988 — intervention group
Group type: EXPERIMENTAL
Intervention: [1‐(13)C]KIC infusion
Number of subjects: 7
Study 10599988 — intervention group
Group type: EXPERIMENTAL
Intervention: [5,5,5‐2H3]KIC infusion
Number of subjects: 7
Study 10599988 — intervention group
Group type: EXPERIMENTAL
Intervention: [1‐(13)C]KIC
Number of subjects: 7
Study 10599988 — intervention group
Group type: EXPERIMENTAL
Intervention: [5,5,5‐2H3]KIC
Number of subjects: 7
Study 10599988 — intervention group
Group type: EXPERIMENTAL
Intervention: [phenyl‐2H5]phenylalanine
Number of subjects: 7
Study 10599988 — intervention group
Group type: EXPERIMENTAL
Intervention: KIC tracer extracted by the splanchnic bed
Number of subjects: 7
Study 8560998 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms misoprostol
Number of subjects: 40
Study 8560998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1663282 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-drug combination of 7-10 mg/kg rifabutin, 5 mg/kg isoniazid, 20 mg/kg ethambutol and 100 mg clofazimine
Number of subjects: 50
Study 6136959 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose isosorbide dinitrate in combination with nadolol
Number of subjects: 19
Study 6136959 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose nifedipine in combination with nadolol
Number of subjects: 19
Study 6136959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol alone and in combination with isosorbide dinitrate or nifedipine
Number of subjects: 19
Study 6136959 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose nifedipine
Number of subjects: 19
Study 6136959 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate in combination with nadolol
Number of subjects: 19
Study 6136959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 19
Study 6136959 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide treatment periods
Number of subjects: 19
Study 6136959 — intervention group
Group type: EXPERIMENTAL
Intervention: Both isosorbide dinitrate and nifedipine
Number of subjects: 19
Study 6136959 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 19
Study 30484683 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable Fortification (AF)
Number of subjects: 60
Study 30484683 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Fortification (TF)
Number of subjects: 60
Study 30484683 — intervention group
Group type: COMPARATOR
Intervention: Standard Fortification (SF)
Number of subjects: 60
Study 28674765 — intervention group
Group type: EXPERIMENTAL
Intervention: AC-T (doxorubicin and cyclophosphamide followed by docetaxel)
Number of subjects: 201
Study 28674765 — intervention group
Group type: COMPARATOR
Intervention: TAC (triplet chemotherapy)
Number of subjects: 201
Study 28674765 — intervention group
Group type: EXPERIMENTAL
Intervention: AC-T
Number of subjects: 201
Study 28674765 — intervention group
Group type: COMPARATOR
Intervention: TAC
Number of subjects: 201
Study 26433116 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature of 33 °C
Number of subjects: 278
Study 26433116 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature of 36 °C
Number of subjects: 278
Study 26433116 — intervention group
Group type: COMPARATOR
Intervention: Control group (STEMI)
Number of subjects: 278
Study 25045824 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-4774 (10, 40, or 80 yeast units)
Number of subjects: 60
Study 25045824 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-4774 (80 yeast units)
Number of subjects: 60
Study 25045824 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-4774
Number of subjects: 60
Study 25045824 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-4774 (10YU: 45%; 40YU: 35%; 80YU: 74%)
Number of subjects: 60
Study 22744970 — intervention group
Group type: EXPERIMENTAL
Intervention: α(1)‐adrenoreceptor blockade with prazosin (0.05 mg/kg)
Number of subjects: 18
Study 22744970 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 18
Study 19204511 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous control of oxygen concentration
Number of subjects: 15
Study 19204511 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 15
Study 17651596 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (Group A)
Number of subjects: 31
Study 17651596 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 31
Study 15061656 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard micronutrient supplementation in patients under long term parenteral nutrition
Number of subjects: 41
Study 15061656 — intervention group
Group type: COMPARATOR
Intervention: Control group of fifty eight blood donors
Number of subjects: 41
Study 11785713 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day course of ranitidine bismuth citrate 400 mg bid, clarithromycin 500 mg bid, and tinidazole 500 mg bid
Number of subjects: 131
Study 11785713 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day course of omeprazole 20 mg bid plus amoxycillin 1 g bid for the first 5 days, and omeprazole 20 mg bid, clarithromycin 500 mg bid and tinidazole 500 mg bid for the remaining 5 days
Number of subjects: 131
Study 9408064 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical oral clodronate with calcium supplementation
Number of subjects: 27
Study 9408064 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation alone
Number of subjects: 27
Study 7690542 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 82
Study 7690542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 3896664 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg pirazolac in the morning and 600 mg at night
Number of subjects: 24
Study 3896664 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg pirazolac given morning and evening
Number of subjects: 24
Study 3896664 — intervention group
Group type: COMPARATOR
Intervention: Overall assessment by 23 patients
Number of subjects: 24
Study 31320345 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured insole (n=35)
Number of subjects: 70
Study 31320345 — intervention group
Group type: COMPARATOR
Intervention: Smooth insole (n=35)
Number of subjects: 70
Study 29143534 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium-based treatment
Number of subjects: 303
Study 29143534 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine-based treatment
Number of subjects: 303
Study 29143534 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased activation
Number of subjects: 303
Study 29143534 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsyndromal manic symptoms
Number of subjects: 303
Study 26825311 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone Airtraq(®) system
Number of subjects: 30
Study 26825311 — intervention group
Group type: COMPARATOR
Intervention: Airtraq(®) laryngoscope
Number of subjects: 30
Study 24643430 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous exercise (CE)
Number of subjects: 15
Study 24643430 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval exercise (IE)
Number of subjects: 15
Study 24643430 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control (CON)
Number of subjects: 15
Study 23867841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (10 mg daily for 6 months)
Number of subjects: 212
Study 23867841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 23867841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 212
Study 20645525 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% lotion
Number of subjects: 2141
Study 20645525 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 2141
Study 17551088 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-directed smoking cessation intervention (n = 38)
Number of subjects: 68
Study 17551088 — intervention group
Group type: COMPARATOR
Intervention: Control group received smoking cessation literature (n = 30)
Number of subjects: 68
Study 17551088 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-directed intervention (n = 38)
Number of subjects: 68
Study 17551088 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sample (n = 68)
Number of subjects: 68
Study 16613886 — intervention group
Group type: EXPERIMENTAL
Intervention: eSET (elective single embryo transfer)
Number of subjects: 0
Study 16613886 — intervention group
Group type: COMPARATOR
Intervention: DET (double embryo transfer)
Number of subjects: 0
Study 14644854 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 20 mg
Number of subjects: 284
Study 14644854 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg
Number of subjects: 284
Study 14644854 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg
Number of subjects: 284
Study 14644854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 10892660 — intervention group
Group type: EXPERIMENTAL
Intervention: isosorbide-5-mononitrate (5-ISMN)
Number of subjects: 22
Study 10892660 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 8831326 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 300 micrograms/kg
Number of subjects: 50
Study 8831326 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 500 micrograms/kg
Number of subjects: 50
Study 8831326 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 150 micrograms/kg
Number of subjects: 50
Study 8831326 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 250 micrograms/kg
Number of subjects: 50
Study 8831326 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 60 micrograms/kg
Number of subjects: 50
Study 8831326 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 100 micrograms/kg
Number of subjects: 50
Study 8831326 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller doses of each drug
Number of subjects: 50
Study 8831326 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger doses of each drug
Number of subjects: 50
Study 1595430 — intervention group
Group type: COMPARATOR
Intervention: 3D FLASH examination
Number of subjects: 61
Study 1595430 — intervention group
Group type: COMPARATOR
Intervention: 3D MP RAGE examination
Number of subjects: 61
Study 1595430 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard examination (Sagittal T1-weighted spin echo, axial low flip angle gradient echo)
Number of subjects: 61
Study 1595430 — intervention group
Group type: COMPARATOR
Intervention: 3D FLASH and 3D MP RAGE examinations
Number of subjects: 61
Study 1595430 — intervention group
Group type: EXPERIMENTAL
Intervention: Single enhanced 3D T1-weighted imaging sequence
Number of subjects: 61
Study 7448140 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended contact lens wear for 18 weeks
Number of subjects: 45
Study 31907860 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored triple therapy (TATT)
Number of subjects: 467
Study 31907860 — intervention group
Group type: COMPARATOR
Intervention: Traditional bismuth-containing quadruple therapy (TRBQT)
Number of subjects: 467
Study 31907860 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored bismuth-containing quadruple therapy (TABQT)
Number of subjects: 467
Study 30759467 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotatable sphincterotome
Number of subjects: 200
Study 30759467 — intervention group
Group type: COMPARATOR
Intervention: Conventional sphincterotome
Number of subjects: 200
Study 30759467 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 200
Study 28946832 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy plus medical management
Number of subjects: 476
Study 28946832 — intervention group
Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 476
Study 26508752 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT) within REVASCAT trial
Number of subjects: 2576
Study 26508752 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT) outside REVASCAT trial
Number of subjects: 2576
Study 26508752 — intervention group
Group type: COMPARATOR
Intervention: Intravenous thrombolysis only
Number of subjects: 2576
Study 23570501 — intervention group
Group type: EXPERIMENTAL
Intervention: E-CMF (epirubicin-containing chemotherapy)
Number of subjects: 288
Study 23570501 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate and fluorouracil)
Number of subjects: 288
Study 21448662 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted gap balancing technique
Number of subjects: 140
Study 21448662 — intervention group
Group type: COMPARATOR
Intervention: Conventional measured resection technique
Number of subjects: 140
Study 19185642 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 290
Study 19185642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 17431226 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with severe pulmonary emphysema
Number of subjects: 1053
Study 17431226 — intervention group
Group type: COMPARATOR
Intervention: Men with severe pulmonary emphysema
Number of subjects: 1053
Study 17133300 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral yohimbine
Number of subjects: 1
Study 17133300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 12733777 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliances
Number of subjects: 0
Study 12733777 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (CPAP)
Number of subjects: 0
Study 12733777 — intervention group
Group type: COMPARATOR
Intervention: Maxillofacial surgery
Number of subjects: 0
Study 10325911 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta agonist reduction group (terbutaline dose reduced from 2500 to 500 micrograms/day)
Number of subjects: 33
Study 10325911 — intervention group
Group type: COMPARATOR
Intervention: Control group (terbutaline dose reduced from 3000 to 2250 micrograms/day)
Number of subjects: 33
Study 7573829 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with depot grass pollen extract (Phleum pratense, Alutard SQ)
Number of subjects: 40
Study 7573829 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued injection treatment (immunotherapy)
Number of subjects: 40
Study 7573829 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 40
Study 1904354 — intervention group
Group type: EXPERIMENTAL
Intervention: L-deprenyl (10 mg/day)
Number of subjects: 119
Study 1904354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 6110955 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cisplatin and chlorambucil
Number of subjects: 98
Study 6110955 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cisplatin, chlorambucil, and doxorubicin
Number of subjects: 98
Study 29471839 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized follow up by nursing personnel from the vascular neurology department including therapeutic follow up and a training program on secondary prevention directed to the patient and a caregiving member of their social circle.
Number of subjects: 410
Study 29471839 — intervention group
Group type: COMPARATOR
Intervention: Usual follow up done by the patient's general practitioner after classical information on secondary prevention of risk factors during hospitalization.
Number of subjects: 410
Study 27094158 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor self-rated health (SRH)
Number of subjects: 321
Study 27094158 — intervention group
Group type: COMPARATOR
Intervention: Good self-rated health (SRH)
Number of subjects: 321
Study 25925343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation
Number of subjects: 30
Study 25925343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22956509 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum levels of IL-17 (below the median)
Number of subjects: 981
Study 22956509 — intervention group
Group type: EXPERIMENTAL
Intervention: High soluble VCAM-1 (sVCAM-1) levels
Number of subjects: 981
Study 22956509 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-17 levels below the median
Number of subjects: 981
Study 20961444 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Therapy (MBCT)
Number of subjects: 420
Study 20961444 — intervention group
Group type: COMPARATOR
Intervention: Maintenance anti-depressant treatment (m-ADM)
Number of subjects: 420
Study 17934830 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole 10 mg
Number of subjects: 3
Study 17934830 — intervention group
Group type: COMPARATOR
Intervention: omeprazole 20 mg
Number of subjects: 3
Study 15902162 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineometer measurements of maximum squeeze pressure
Number of subjects: 100
Study 15902162 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineometer measurements of average pressure
Number of subjects: 100
Study 15902162 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineometer measurements of total duration
Number of subjects: 100
Study 15902162 — intervention group
Group type: COMPARATOR
Intervention: Brink assessment
Number of subjects: 100
Study 15902162 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineometer measurements
Number of subjects: 100
Study 12638112 — intervention group
Group type: EXPERIMENTAL
Intervention: Children after TBI
Number of subjects: 20
Study 12638112 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20